Jacobs Levy Equity Management
CYCN icon

Jacobs Levy Equity Management’s Cyclerion Therapeutics CYCN Stock Holding History

Jacobs Levy Equity Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,564
Closed -$280K – 991
2021
Q3 		$280K Buy
+4,564
New +$299K ﹤0.01% 944
2021
Q2 		– Sell
-9,910
Closed -$553K – 1049
2021
Q1 		$553K Buy
9,910
+4,675
+89% +$351K ﹤0.01% 850
2020
Q4 		$320K Sell
5,235
-768
-13% -$52.4K ﹤0.01% 912
2020
Q3 		$730K Sell
6,003
-1,517
-20% -$173K 0.01% 718
2020
Q2 		$889K Buy
7,520
+2,334
+45% +$195K 0.01% 695
2020
Q1 		$275K Sell
5,186
-6,116
-54% -$436K ﹤0.01% 837
2019
Q4 		$615K Buy
11,302
+7,576
+203% +$707K 0.01% 758
2019
Q3 		$903K Buy
3,726
+2,926
+366% +$632K 0.01% 628
2019
Q2 		$183K Buy
+800
New +$226K ﹤0.01% 883

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management's CYCN Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 4,564 shares — an estimated $280K sold.

Jacobs Levy Equity Management first reported a position in CYCN in Q2 2019 and held it in 9 quarters. The position peaked at $903K in Q3 2019. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 4,564 Cyclerion Therapeutics shares in Q4 2021, an estimated $280K.
  • Jacobs Levy Equity Management first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 9 quarters.
  • Jacobs Levy Equity Management's Cyclerion Therapeutics position peaked at $903K in Q3 2019.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.